Dish of the day
*A corporate client of Hybridan LLP
No Joiners Today
Off the menu
No Leavers Today
What’s cooking in the IPO kitchen?
The pantry is empty
The global immunodiagnostics group today announces that it has signed a foothill contract to utilise the Company’s Early CDT Lung panel to detect incident lung cancer cases in a screening setting. With one of the world’s largest pharmaceutical companies, Oncimmune will further evaluate EarlyCDT Lung for the detection of lung cancer in at-risk patients. The initial phase of the collaboration will assess the utility of Early CDT Lung test at detecting incident lung cancer cases in a screening setting. Oncimmune expects this initial phase to be the first step towards a long term partnership to generate widespread availability of the EarlyCDT Lung test to improve early detection of lung cancer and facilitate earlier treatment.
Randall & Quilter 135p £288m (AIM:RQIH)
The non-life global specialty insurance company focusing on the Program Management and Legacy Insurance businesses, today announces the appointment of Thomas (Tom) Solomon as Group Chief Financial Officer (CFO). Tom will also be appointed to the Company’s board of directors later in the year. Tom joins R&Q from his current position as Managing Director and Head of Americas Insurance Investment Banking at Bank of America. He has previously held senior positions at Citigroup and PricewaterhouseCoopers, LLP. Tom has an MBA in Finance and Economics from Columbia Business School and is a member of the Society of Actuaries. Tom will be based in R&Q’s New York office and report to William Spiegel, Group Deputy Executive Chairman.
ClearStar 48.2p £17.5m (AIM:CLSU)
The provider of Human Capital Integrity℠ technology-based services specialising in background and medical screening, announces the launch of a testing service aimed at supporting employers with their COVID-19 return-to-work planning and keeping their workforce safe. The new service is provided by ClearStar’s Medical Information Services business through Clinical Reference Laboratory, Inc., one of the largest privately held clinical testing laboratories in the US, and it includes both an antibody and a diagnostic test. In the first instance, employees receive the CRL Clear™ kit, which is a dried blood spot finger prick test that is used to identify the presence, or lack, of COVID-19 antibodies in the blood, which are produced by the body in response to the virus. This includes IgA, IgM and IgG antibodies, which are produced at different stages of the immune system response. A positive test result indicates that the employee has been previously infected by COVID-19 and has developed antibodies that might provide the employee with immunity.
The business recovery, financial advisory and property services consultancy, announces an update on trading for its financial year ended 30 April 2020. Results broadly in line with market expectations: Revenue expected to be c.£70m (2019: £60.1m), adjusted PBT expected to be c.£9.2m (2019: £7.0m), having absorbed a £0.6m impact of the lockdown in the last six weeks of the financial year. “Looking ahead we remain well placed, given our strong financial position, the likely impact of the COVID-19 pandemic on the UK economy and the counter-cyclical focus of our business.”
MTI Wireless Edge 38.5p £33.8m (AIM:MWE)
The technology group focused on comprehensive communication and radio frequency solutions across multiple sectors announced that its subsidiary, Mottech Water Solutions Ltd, a provider of wireless irrigation control solutions, has signed an agreement to acquire its joint venture partner’s 40% holding in a joint venture it established in China in 2017. Following this acquisition, Mottech China is now a fully owned subsidiary of the Company. As announced in 2017, Mottech and its representative in China established this joint venture in order to pursue the Chinese market and now Mottech is strengthening its presence in this market. China has become Mottech’s fastest growing market and the team are focused on supplying solutions to Chinese municipalities and large scale agricultural organisations as they seek to better manage their water resources and adapt to climate change.
Kape Technologies 201p £311m (AIM:KAPE)
Kape has made a strong start to 2020, despite the global macroeconomic disruption caused by the COVID-19 pandemic. As announced on 31 March 2020, Kape has experienced increased demand for its products as working remotely has become commonplace across the globe in response to COVID-19. Within the Digital Privacy segment, new monthly sign-ups in April 2020 increased by 19% to the comparable period in 2019 on a proforma basis. The Company remains on track to deliver revenues of $120-123m and adjusted EBITDA1 of $35-38m in 2020. The integration of PIA continues to progress to plan and management are confident in delivering at least the $3.5-4.5m in cost synergies, as outlined at the time of the acquisition, in the current financial year.
Empyrean Energy 4.95p £23.3m (AIM:EME)
Results of its seismic inversion project, designed to assess the reservoir quality and reservoir rock composition at its Jade and Topaz prospects at Block 29/11 in the Pearl River Mouth Basin, offshore China. Reservoir rocks at Jade and Topaz interpreted to be excellent quality carbonates, porosities at Jade and Topaz interpreted to be in the highly favourable range of 20-30%, and an excellent cooperation between the Empyrean, COSL and CNOOC technical teams delivers a robust dataset resulting in significant technical confidence in the results.
NQ Minerals 6.75p £22.9m (AQSE:NQMI)
The base and precious metals producer from its Hellyer Gold Mine in Tasmania Australia announces that it has raised GBP189,500 (gross) at 7 and 7.5 pence per share from a UK based Institutional investor and a group of private investors for general working capital purposes. The Company is also planning to re-open the historic high-grade Beaconsfield Gold Mine in Tasmania, which has a JORC 2012 compliant Mineral Resource Estimate of 1.454 Mt at 10.3 g/t Au for 483,000 ounces of gold.
Rutherford Health 227.5p £450m (AQSE:RUTH)
The Company has entered into a framework agreement with NHS Shared Business Services, under which it is able to provide cancer treatment services on demand by any NHS Trust at a pre-agreed set of prices. The agreement lasts for two years with an option to extend for a further two years on the agreement of both parties. The agreement covers the complete range of services that Rutherford offers, including radiotherapy, systemic anti-cancer therapy (chemotherapy), proton beam therapy and diagnostic services.
Feedback 1.05p £5.7m (LON:FDBK)
The specialist medical imaging technology companytoday announces Royal Papworth Hospital NHS Foundation Trust has renewed its contract for clinical PACS (picture archiving and communication system) services with Feedback Medical Ltd, a wholly owned subsidiary of the Company. The renewal will incorporate an upgrade to service, providing the Trust access to Bleepa®, Feedback’s flagship imaging-based communication platform. The contract, set for a term of 14 months, rel ates to Feedback’s Cadran PACS which has provided core medical imaging services to the Trust since 2001. The contract includes the use of Bleepa® as an upgrade to Cadran Web Viewer and will see Bleepa® made available to all clinicians at the Trust. For Feedback, the contract marks the second NHS site to adopt Bleepa® as a core imaging tool and is further recognition of the potential that Bleepa® has to enhance clinical care delivery. The first site was the Pennine Acute NHS Hospitals Trust which is using Bleepa® to support frontline staff to manage Covid-19 patients.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.
0203 764 2344